Different therapeutic approaches on quality of life in patients with inflammatory bowel disease

BMC Gastroenterology

Zhihua Ran¹  Jun Shen¹  Minyue Tang³  Xu Feng²  Hui Lin²  Junjie Xu² 

[1] Division of Gastroenterology and Hepatology, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology &Hepatology, Ministry of Health, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute,Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China;Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China;Department of Reproduction, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China

关键词: Infliximab;    Inflammatory bowel disease questionnaire;    Health-related quality of life;    Inflammatory bowel disease;   

Others  :  1121757
DOI  :  10.1186/s12876-014-0199-5

 received in 2014-07-28, accepted in 2014-11-10,  发布年份 2014

【 摘 要 】

Background

The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated.

Methods

Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment.

Results

MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048).

Conclusions

MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD.

【 授权许可】

   
2014 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kaser A, Zeissig S, Blumberg RS: Inflammatory bowel disease. Annu Rev Immunol 2010, 28:573-621.
• [2]Casellas F, Lopez-Vivancos J, Casado A, Malagelada JR: Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res 2002, 11(8):775-781.
• [3]Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN: The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006, 4(12):1491-1501.
• [4]Larsson K, Loof L, Ronnblom A, Nordin K: Quality of life for patients with exacerbation in inflammatory bowel disease and how they cope with disease activity. J Psychosom Res 2008, 64(2):139-148.
• [5]Faust AH, Halpern LF, Danoff-Burg S, Cross RK: Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life. Gastroenterol Hepatol 2012, 8(3):173-181.
• [6]Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR: Sustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007, 13(11):1395-1400.
• [7]Tursi A, Elisei W, Brandimarte G, Giorgetti G, Penna A, Castrignano V: Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice. Eur Rev Med Pharmacol Sci 2010, 14(1):47-55.
• [8]Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: ACCENT I Study Group: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
• [9]Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476.
• [10]Koelewijn C, Schrijvers A, Oldenburg B: Infliximab use in patients with Crohn’s disease: quality of life, costs and resource use. Neth J Med 2006, 64(7):212-218.
• [11]Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB: The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007, 102(4):794-802.
• [12]Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR: The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003, 98(10):2232-2238.
• [13]Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C: A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96(3):804-810.
• [14]Pallis AG, Mouzas IA, Vlachonikolis IG: The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004, 10(3):261-269.
• [15]Ren WH, Lai M, Chen Y, Irvine EJ, Zhou YX: Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 2007, 13(7):903-910.
• [16]Zheng JJ, Zhu XS, Huangfu Z, Shi XH, Guo ZR: Prevalence and incidence rates of Crohn’s disease in mainland China: a meta-analysis of 55 years of research. J Dig Dis 2010, 11(3):161-166.
• [17]Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, LeMair AW, Malfertheiner , Ouyang Q, Rey JF, Sood A, Steinwurz F, Thomsen OO, Thomson A, Watermeyer G: World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010, 16(1):112-124.
• [18]Irvine EJ, Feagan BG, Wong CJ: Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996, 49(10):1177-1185.
• [19]Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 1992, 30(6):473-483.
• [20]Pan X, Ding C, Pan Y, Zhang A, Wu B, Huang H, Zhu C, Liu D, Zhu B, Xu G, Shao H, Peng S, Jiang X, Zhao C, Han C, Ji H, Yu S, Zhang X, Zhang L, Zheng Y, Yan H: Distribution of copper and zinc in blood among general population from 8 provinces in China. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2014, 48(2):109-113.
• [21]Li L, Wang HM, Shen Y: Chinese SF-36 health survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 2003, 57(4):259-263.
• [22]Harvey RF, Bradshaw JM: A simple index of Crohn’s-disease activity. Lancet 1980, 1(8167):514.
• [23]Walmsley RS, Ayres RC, Pounder RE, Allan RN: A simple clinical colitis activity index. Gut 1998, 43(1):29-32.
• [24]Tarumi K, Imanaka Y, Isshiki Y, Morimoto K: Quality of life domains in the healthy public: a trial investigation using attendants for an annual health checkup. Environmental Health Prev Med 1999, 4(1):39-48.
• [25]Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, Francis J, Speroff T, Gautam S, Margolin R, Sessler CN, Dittus RS, Bernard GR: Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003, 289(22):2983-2991.
• [26]Leong RW, Lee YT, Ching JY, Sung JJ: Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire. Aliment Pharmacol Ther 2003, 17(5):711-718.
• [27]Romberg-Camps MJ, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MA, Kester AD, Engels LG, van Deursen C, Hameeteman WH, Pierik M, Wolters F, Russel MG, Stockbrügger RW: Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis 2010, 16(12):2137-2147.
• [28]Hamid OA, El Fiky LM, Medani MM, Abdelhady A, Ali HH: Laryngeal cancer in Egypt: quality of life measurement with different treatment modalities. Head Neck 2011, 33(8):1162-1169.
• [29]Galbraith ME, Ramirez JM, Pedro LW: Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum 2001, 28(3):551-560.
• [30]Ciccocioppo R, Klersy C, Russo ML, Valli M, Boccaccio V, Imbesi V, Ardizzone S, Porro GB, Corazza GR: Validation of the Italian translation of the inflammatory bowel disease questionnaire. Dig Liver Dis 2011, 43(7):535-541.
• [31]Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW: Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994, 106(2):287-296.
• [32]Clearfield HR: How does IBD affect quality of life? Inflamm Bowel Dis 2008, 14 Suppl 2:S45-S46.